Zydus publishes Phase 3 trial results of Desidustat in the American Journal of Nephrology
Desidustat's development is based on the Nobel Prize in Medicine winning science on discoveries of the oxygen sensing mechanism of cells through hypoxia-inducible factor (HIF). Desidustat works by stabilizing the HIF complex and stimulating endogenous erythropoietin production in Chronic kidney disease (CKD) patients thereby improving haemoglobin levels and treating anemia. CKD patients irrespective of their dialysis status
have been reported to develop anemia leading to significant morbidity, mortality, progression of kidney disease and higher blood transfusion rates. Chronic Kidney Disease patients are often on 8-13 different medications and are at safety risks of drug-drug interactions.